INSTANT FUNDING via Increasing BIEL PPS
A rising BIEL Price Per Share (PPS) does not directly put cash into Electrome’s bank account — but it instantly strengthens Electrome’s ability to secure capital by improving valuation, leverage, credibility, and investor confidence.
1️⃣ Higher PPS = Instant Validation - Higher Valuation for Electrome’s $3M Pre‑Seed Round
Electrome is actively raising a $3.0M pre‑seed round. Their business model is built on:
Exclusive distribution rights to ActiPatch® and RecoveryRx®
Integration into Electrome’s AI‑native PAINKILLER™ platform
When BIEL’s PPS rises because the market recognizes the strength of this partnership, it validates Electrome’s model in real time. This gives Electrome:
A higher valuation ceiling
Faster close times
Less dilution
More investor competition
VCs and angels see Electrome as de‑risked and “highly viable” when BIEL’s PPS is rising.
2️⃣ Higher PPS = Leverage for Equity Deals, JV Expansion, and Venture Debt
When a partner’s stock rises, the economic ecosystem around them strengthens. This creates multiple funding pathways:
A) Equity Swaps & Strategic Investment
If BIEL’s PPS rises and its market cap expands, BIEL gains the ability to:
Take an equity stake in Electrome
Inject capital
Expand the joint venture
BIEL could directly fund Electrome, take an equity stake… or expand their joint venture when the PPS rises.
Venture Debt & Institutional Lending
A rising PPS makes Electrome’s distribution agreements look:
More secure
More scalable
More revenue‑generating
This increases Electrome’s attractiveness to lenders and venture debt firms.
3️⃣ Higher PPS = Public Proof of Commercial Traction
BIEL’s PPS is “highly sensitive to distribution and sales volume. Electrome is already selling into:
VA health system
High‑margin institutional networks (~87% margins)
So when BIEL’s PPS rises, investors interpret it as:
Electrome is selling
Electrome is scaling
Electrome is executing
A rising PPS is a public indicator that the product is moving and the market is responding. This is the kind of traction that closes funding rounds instantly.
4️⃣ Electrome Could Buy a Stake in BIEL and Generate Funding From PPS Appreciation
Electrome could choose to purchase a strategic stake in BIEL while PPS is still at micro‑levels ($0.0004). This creates a self‑reinforcing funding engine:
A) Electrome Buys BIEL Shares at Low PPS
Because BIEL is trading at a valuation that “implies dormant shell” despite entering hyper‑growth commercialization , Electrome can accumulate a meaningful position at extremely low cost.
Electrome Benefits Directly From PPS Appreciation
As Electrome scales:
VA sales increase
CMS channels open
3,700‑pharmacy rollout activates
AI therapeutics layer expands
BIEL’s PPS rises accordingly. Electrome’s stake becomes:
A liquid asset
A balance‑sheet enhancer
A non‑dilutive funding source
C) Electrome Can Sell Appreciated Shares to Fund Operations
If Electrome buys BIEL at $0.0004 and PPS later reprices, Electrome can:
Sell a portion of its stake
Generate instant liquidity
Fund operations without dilution
Finance expansion without debt
This is a VC‑style flywheel:
Electrome drives BIEL’s growth
BIEL’s PPS rises
Electrome’s stake appreciates
Electrome gains funding
Electrome scales further
BIEL’s PPS rises again.
This is the definition of a self‑reinforcing capital engine.
Summary
A rising BIEL PPS gives Electrome instant funding power — not by depositing cash, but by strengthening every financial lever Electrome needs to scale.
It provides:
Instant validation for Electrome’s $3M raise
Leverage for equity deals and JV expansion
Credibility with lenders and venture debt firms
Public proof of commercial traction
A new funding engine if Electrome buys a stake in BIEL and benefits from PPS appreciation
A rising PPS makes securing funding much easier — because it strengthens Electrome’s valuation, narrative, and financial optionality across the board.
A rising BIEL Price Per Share (PPS) does not directly put cash into Electrome’s bank account — but it instantly strengthens Electrome’s ability to secure capital by improving valuation, leverage, credibility, and investor confidence.
1️⃣ Higher PPS = Instant Validation - Higher Valuation for Electrome’s $3M Pre‑Seed Round
Electrome is actively raising a $3.0M pre‑seed round. Their business model is built on:
Exclusive distribution rights to ActiPatch® and RecoveryRx®
Integration into Electrome’s AI‑native PAINKILLER™ platform
When BIEL’s PPS rises because the market recognizes the strength of this partnership, it validates Electrome’s model in real time. This gives Electrome:
A higher valuation ceiling
Faster close times
Less dilution
More investor competition
VCs and angels see Electrome as de‑risked and “highly viable” when BIEL’s PPS is rising.
2️⃣ Higher PPS = Leverage for Equity Deals, JV Expansion, and Venture Debt
When a partner’s stock rises, the economic ecosystem around them strengthens. This creates multiple funding pathways:
A) Equity Swaps & Strategic Investment
If BIEL’s PPS rises and its market cap expands, BIEL gains the ability to:
Take an equity stake in Electrome
Inject capital
Expand the joint venture
BIEL could directly fund Electrome, take an equity stake… or expand their joint venture when the PPS rises.
Venture Debt & Institutional Lending A rising PPS makes Electrome’s distribution agreements look:
More secure
More scalable
More revenue‑generating
This increases Electrome’s attractiveness to lenders and venture debt firms.
3️⃣ Higher PPS = Public Proof of Commercial Traction
BIEL’s PPS is “highly sensitive to distribution and sales volume. Electrome is already selling into:
VA health system
High‑margin institutional networks (~87% margins)
So when BIEL’s PPS rises, investors interpret it as:
Electrome is selling
Electrome is scaling
Electrome is executing
A rising PPS is a public indicator that the product is moving and the market is responding. This is the kind of traction that closes funding rounds instantly.
4️⃣ Electrome Could Buy a Stake in BIEL and Generate Funding From PPS Appreciation
Electrome could choose to purchase a strategic stake in BIEL while PPS is still at micro‑levels ($0.0004). This creates a self‑reinforcing funding engine:
A) Electrome Buys BIEL Shares at Low PPS
Because BIEL is trading at a valuation that “implies dormant shell” despite entering hyper‑growth commercialization , Electrome can accumulate a meaningful position at extremely low cost.
Electrome Benefits Directly From PPS Appreciation As Electrome scales:
VA sales increase
CMS channels open
3,700‑pharmacy rollout activates
AI therapeutics layer expands
BIEL’s PPS rises accordingly. Electrome’s stake becomes:
A liquid asset
A balance‑sheet enhancer
A non‑dilutive funding source
C) Electrome Can Sell Appreciated Shares to Fund Operations
If Electrome buys BIEL at $0.0004 and PPS later reprices, Electrome can:
Sell a portion of its stake
Generate instant liquidity
Fund operations without dilution
Finance expansion without debt
This is a VC‑style flywheel:
Electrome drives BIEL’s growth
BIEL’s PPS rises
Electrome’s stake appreciates
Electrome gains funding
Electrome scales further
BIEL’s PPS rises again.
This is the definition of a self‑reinforcing capital engine.
Summary
A rising BIEL PPS gives Electrome instant funding power — not by depositing cash, but by strengthening every financial lever Electrome needs to scale.
It provides:
Instant validation for Electrome’s $3M raise
Leverage for equity deals and JV expansion
Credibility with lenders and venture debt firms
Public proof of commercial traction
A new funding engine if Electrome buys a stake in BIEL and benefits from PPS appreciation
A rising PPS makes securing funding much easier — because it strengthens Electrome’s valuation, narrative, and financial optionality across the board.
1
